Savient makes executive appointments
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals is strengthening its management team with three new appointments as it begins the commercial launch of its gout therapy Krystexxa (pegloticase). Louis Ferrari will join as senior vice-president of North America commercial, Christine Mikail will become senior vice-president of corporate development and Stephen Davies becomes chief information officer and group vice president. Mr Ferrari was previously as vice-president of oncology and nephrology, sales and marketing at Centocor Ortho Biotech; Ms Mikail served as vice-president, general counsel and secretary for ImClone Systems; while Mr Davies was also previously at ImClone, where he as vice-president of information technology.